DBV Technologies Set to Showcase Innovations at ACAAI 2024
DBV Technologies (NASDAQ: DBVT), a pioneering clinical-stage biopharmaceutical company, is gearing up for its participation at the prestigious American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific Meeting. Scheduled from October 24 to October 28, 2024, this event aims to enhance understanding and collaboration in the field of allergy and immunology.
Focus on Optimal Treatments for Peanut Allergies
This year's congress will feature an insightful session titled "What Defines an Optimal Peanut Allergy Treatment?" Drs. Shahzad Mustafa, Edwin Kim, and Julia Upton, along with Eleanor Garrow-Holding, CEO of Food Allergy Research and Education (FAACT), will contribute their expertise to this engaging panel discussion. Set for October 26th, from 11:35 AM to 1:00 PM EDT, the Product Theater will delve into key aspects of designing effective treatments for peanut allergies, emphasizing efficacy, safety, and practicality.
DBV's Involvement in the ACAAI Annual FIT Bowl
In addition to the Product Theater session, DBV Technologies is excited to be a sponsor of the 33rd Annual FIT Bowl competition. This fun, game show-like event challenges teams' knowledge in allergy, asthma, and immunology from various training programs across the nation. The competition will be held on October 26th, from 5:45 PM to 7:45 PM EDT, offering a unique blend of learning and entertainment.
Transforming Food Allergy Treatments
DBV Technologies is deeply committed to addressing the urgent medical needs associated with food allergies. The company is particularly focused on advancing its proprietary Viaskin® technology, which employs epicutaneous immunotherapy (EPIT™) to introduce allergen extracts to the immune system. This innovative approach aims to desensitize individuals suffering from peanut allergies by leveraging non-invasive treatment options.
Insights from Leadership
Dr. Pharis Mohideen, Chief Medical Officer of DBV Technologies, expressed enthusiasm about the upcoming ACAAI participation. "We are very pleased to join our peers in food allergy at ACAAI again this year, particularly after recently completing enrollment for our VITESSE study involving children aged 4 to 7 years," he noted. The collaboration has marked a significant milestone in DBV's journey to provide better therapeutic options for those affected by food allergies.
DBV Technologies and Its Commitment to Patients
DBV Technologies operates with a mission to transform the management of food allergies. The company is not only dedicated to finding solutions for peanut allergies but also addresses other severe immunological conditions faced by many. Through clinical trials and innovative research, DBV aims to improve the lives of countless individuals living with food allergies.
Understanding Viaskin® Patch Technology
The Viaskin® Peanut patch epitomizes DBV's commitment to innovation. This investigational product candidate is designed to help reduce the risk of allergic reactions to peanuts. It symbolizes a promising step forward as an epicutaneous, once-daily patch that aims to deliver precise quantities of peanut protein for immune system re-education. Although not yet approved by regulatory agencies, its potential impact is substantial.
Connecting with DBV Technologies
DBV's main operational base is situated in Châtillon, France, complemented by its North American hub in Warren, New Jersey. Their ordinary shares are traded on Euronext Paris (PARIS:DBV), while their American Depositary Shares on Nasdaq (NASDAQ: DBVT) reflect their global outreach and commitment to advancing food allergy treatment.
For those interested in learning more, additional resources can be found on their official website, and active communication channels exist for both investors and media inquiries. DBV Technologies maintains an active presence on social platforms, allowing them to engage directly with the community.
Frequently Asked Questions
What is the focus of DBV Technologies at ACAAI 2024?
DBV Technologies is focusing on discussing optimal treatments for peanut allergies and showcasing their innovative Viaskin® technology.
When will the Product Theater session occur?
The Product Theater session titled "What Defines an Optimal Peanut Allergy Treatment?" is scheduled for October 26th from 11:35 AM to 1:00 PM EDT.
What is the Viaskin® Peanut patch?
The Viaskin® Peanut patch is a non-invasive treatment designed to help patients with peanut allergies by delivering microgram quantities of peanut allergen to re-educate the immune system.
What is the purpose of the FIT Bowl competition?
The FIT Bowl competition tests participants' knowledge of allergy, asthma, and immunology while fostering a sense of community among training programs.
How can I learn more about DBV Technologies?
More information can be found on DBV Technologies' official website and various social media platforms.
